Therapie der weiblichen OAB

Zusammenfassung

Das Syndrom der überaktiven Harnblase (OAB) mit den Symptomen Frequency, Urgency und Nykturie ist häufig. Nach sorgfältiger Ausschlussdiagnostik stehen verschiedene symptomatische Therapiestrategien zur Verfügung, die neben einer medikamentösen Therapie minimal-invasive operative Maßnahmen beinhalten und auch in die Steuerung der Harnblase eingreifen durch Modulation zentralnervöser Zentren. Alternative Methoden wie die Akupunktur können im Einzelfall helfen, die Placebo-Wirkung ist hoch, kontrollierte Studien fehlen.

Abstract

The syndrome of overactive bladder (OAB) with the symptoms of frequency, urgency and nocturia is often seen. After the diagnosis has been made by careful exclusion of other conditions, there are different symptomatic treatment strategies available. These include drug treatment as well as minimally invasive local surgical treatments and treatments which intervene with the control of the bladder by modulating central nervous areas. Alternative methods such as acupuncture may help in individual cases; the placebo effect is high and there is a lack of controlled studies.

Schlüsselwörter

Syndrom der überaktiven Blase - OAB - Anticholinergika - Sakrale Neuromodulation - Botulinumtoxin

Key words

overactive bladder - OAB - anticholinergics - sacral neuromodulation - botulinum toxin

• Literatur

• 1 Abrams P, Cardozo L, Fall M et al. The Standardisation of Terminology of Lower Urinary Tract Function. Neurourol Urodyn 2002; 21: 167-178
• 2 Anger JT. How dry is “OAB-dry”? Perspectives from patients and physician experts. J Urol 2012; 188: 1811-1815
• 3 Homma Y. Lower urinary tract symptomatology: Its definition and confusion. Int J Uro 2008; 15: 35-43
• 4 Gormley EA, Lightner DJ, Faraday M et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment. J Urol 2015; 193: 1572-1580
• 5 Gibbs RS. Danforth's obstetrics and gynecology. 10 (ed.). Philadelphia: Lippincott Williams & Wilkins; 2008: 890-891
• 6 Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188 (6 Suppl) 2455-2463
• 7 Sussmann DO. Overactive bladder: treatment options in primary care medicine. J Am Osteopathic Ass 2007; 107: 379-385
• 8 Hartmann KE, McPheeters ML, Biller DH et al. Treatment of overactive bladder in women. Evidence Rep Technol Assess 2009; 187: 1-120
• 9 Arruda RM, Castro R, Sartori M et al. Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: A review. Curr Opinion Obstet and Gyn 2009; 21: 412-414
• 10 Nitti VW, Auerbach S, Martin N et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013; 189: 1388-1395
• 11 Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013; 63: 283-295
• 12 Dmochowski R, Chapple, Nitti VW. et al. Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. J Urol 2010; 184: 2416-2422
• 13 Nitti VW, Dmochowski R, Herschorn S et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013; 189: 2186-2193
• 14 Giannantoni A, Proietti S, Costantini E et al. OnabotulinumtoxinA intravesical treatment in patients affected by overactive bladder syndrome: best practice in real-life management. Urologia 2015; 82: 179-183
• 15 Chancellor MB, Patel V, Leng WW et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology 2013; 81: 841-848
• 16 Apostolidis A, Dasgupta P. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunction: a European Consensus panel record. Eur Urol 2009; 55: 100-120
• 17 Jünnemann KP, Nitti VW, Chartier-Kastler E et al. Urologe 2015; 54 (Suppl. 01) 19
• 18 Mohee A, Khan A, Harris N et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013; 111: 106-113
• 19 Veeratterapillay R, Harding C, Teo L et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol 2014; 21: 175-178
• 20 Dowson C, Watkins J, Khan MS et al. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012; 61: 834-839
• 21 Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 1988; 140: 1331-1339
• 22 Kessler TM, Fowler C. Sacral neuromodulation for urinary retention. Nat Clean Pract Urol 2008; 5: 657-666
• 23 Jonas U, Fowler CJ, Chancellor MB et al. Efficacy of sacral nerve stimulation for urinary retention: results18 months after implantation. J Urol 2001; 165: 15-19
• 24 Leng WW, Chancellor MG. How sacral nerve stimulation neuromodulation works. Urol Clin North Am 2005; 32: 11-18
• 25 Fowler CJ, Christmas TJ, Chapple CR et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome?. BMJ 1988; 297: 1436-1438
• 26 Dasgupta R, Critchley HD, Dolan RJ et al. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005; 174: 2268-2272
• 27 Groen J, Ruud Bosch JL, Mastrigt R. van Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. J Urol 2006; 175: 1005-1009
• 28 Sievert KD, Amend B, Gakis G et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010; 67: 74-84
• 29 Spinelli M, Sievert KD. Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: Impact on treatment success and safety. Eur Urol 2008; 54: 1287-1296
• 30 Kessler TM, Madersbacher H, Kiss G. Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?. Eur Urol 2005; 47: 660-665
• 31 Huwyler M, Kiss G, Burkhard FC et al. Microbiological tined-lead examination: does prolonged sacral neuromodulation testing induce infection?. BJU Int 2009; 104: 646-650
• 32 Kirschner-Hermanns R, Jakse G. Magnet stimulation therapy: a simple solution for the treatment of stress and urge incontinence?. Urologe A 2003; 42: 819-822
• 33 Kirschner-Hermanns R, Jakse G. Magnetic stimulation of the pelvic floor in older patients. Results of a prospective analysis. Urologe A 2007; 46: 377-381
• 34 Unsal A, Saglam R, Cimentepe E. Extracorporeal magnetic stimulation for the treatment of stress and urge incontinence in women–results of 1-year follow-up. Scand J Urol Nephrol 2003; 37: 424-428
• 35 Chandi DD, Groenendijk PM, Venema PL. Functional extracorporeal magnetic stimulation as a treatment for female urinary incontinence: 'the chair'. BJU Int 2004; 93: 539-542
• 36 Voorham-van der Zalm PJ, Pelger RC, Stiggelbout AM et al. Effects of magnetic stimulation in the treatment of pelvic floor dysfunction. BJU Int 2006; 97: 1035-1038
• 37 Quek P. A critical review on magnetic stimulation: what is its role in the management of pelvic floor disorders?. Curr Opin Urol 2005; 15: 231-235
• 38 MacPherson H, Hammerschlag R, Lewith G. Acupuncture research strategies for establishing an evidence base. Churchill Livingstone Elsevier; 2007
• 39 Kawakita K, Okada K. Acupuncture therapy: mechanism of action, efficacy, and safety: a potential intervention for psychogenic disorders?. Biopsychosoc Med 2014; 8: 4
• 40 Emmons SL, Otto L. Acupuncture for overactive bladder: a randomized controlled trial. Obstet Gynecol 2005; 106: 138-143
• 41 Aydoğmuş Y, Sunay M, Arslan H et al. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial. Urol Int 2014; 93: 437-443
• 42 Yuan Z, He C, Yan S et al. Acupuncture for overactive bladder in female adult: a randomized controlled trial. World J Urol 2015; 33: 1303-1308
• 43 Mo Q, Wang Y, Ye Y et al. Acupuncture for adults with overactive bladder: a systematic review protocol. BMJ Open 2015; 5: e006756
• 44 Forde JC, Jaffe E, Stone BV et al. The role of acupuncture in managing overactive bladder; a review of the literature. Int Urogynecol J 2016;
• 45 Paik SH, Han SR, Kwon OJ et al. Acupuncture for the treatment of urinary incontinence: A review of randomized controlled trials. Exp Ther Med 2013; 6: 773-780
• 46 Ogushi T, Takahashi S. Effect of Chinese herbal medicine on overactive bladder. Hinyokika Kiyo 2007; 53: 857-862
• 47 Kajiwara M, Mutaguchi K. Clinical efficacy and tolerability of gosha-jinki-gan, Japanese traditional herbal medicine, in females with overactive bladder. Hinyokika Kiyo 2008; 54: 95-99
• 48 Dongil K, Changmin C, Insuk A et al. Efficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial. Int J Clin Exp Med 2014; 7: 2744-2753
• 49 Cooperstein R, Lisi A, Burd A. Chiropractic management of pubic symphysis shear dysfunction in a patient with overactive bladder. J Chiropr Med 2014; 13: 81-89